IP Library Patent Application 19298559
Patent Application
App. No. 19/298,559

FAR-RED DYE PROBE FORMULATIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/298,559
Abstract

Disclosed are formulations, including both liquid and lyophilized formulations, comprising a far-red dye probe and a non-linear surfactant or foamban. Also disclosed are related methods for preparing a lyophilized far-red dye probe formulation as well as related kits and diagnostic products.

Claims (31)

1 . A method of preparing a stabilized, aqueous far-red dye probe formulation, the method comprising:

dissolving a far-red dye probe comprising a far-red dye conjugated to a carrier molecule in a diluent to provide a stabilized, aqueous far-red dye probe formulation comprising:

the far-red dye probe;

a non-linear surfactant at a concentration from about 0.5% (v/v) to about 20% (v/v); and

at least one buffering agent;

wherein the far-red dye probe formulation is an aqueous solution.

2 . The method of claim 1 , wherein the diluent comprises the non-linear surfactant.

3 . The method of claim 1 , wherein the non-linear surfactant is selected from the group consisting of a polyoxyethylene sorbitan fatty acid ester and digitonin.

4 . The method of claim 1 , wherein the non-linear surfactant is a polyoxyethylene sorbitan fatty acid ester selected from the group consisting of polysorbate 20, polysorbate 40, and polysorbate 60.

5 . The method of claim 1 , wherein the non-linear surfactant concentration is from about 0.5% (v/v) to about 10% (v/v), from about 1% (v/v) to about 20% (v/v), or from about 1% (v/v) to about 10% (v/v).

6 . The method of claim 21 , wherein the far-red dye is a far-red cyanine dye.

7 . The method of claim 6 , wherein the far-red cyanine dye is selected from the group consisting of cyanine 5 and cyanine 5.5.

8 . The method of claim 1 , wherein the far-red dye probe in the stabilized, aqueous far-red dye probe formulation has a relative fluorescence, in relative fluorescence units (RFU), and the relative fluoresce of far-red dye probe is decreased by no more than 20% after 30 days of storage.

9 . The method of claim 1 , wherein the at least one buffering agent comprises Tris.

10 . The method of claim 9 , wherein the Tris buffering agent is present in the far-red dye probe formulation at a concentration of from about 5 mM to about 50 mM.

11 . The method of claim 1 , wherein the far-red dye probe is present in a lyophilized composition before being dissolved in the diluent.

12 . A diagnostic product comprising a sealed container containing a stabilized far-red dye probe formulation comprising:

a far-red dye probe comprising a far-red dye conjugated to a carrier molecule;

a non-linear surfactant at a concentration from about 0.5% (v/v) to about 20% (v/v); and

at least one buffering agent;

wherein the formulation is an aqueous solution, and further wherein:

(i) the non-linear surfactant is selected from the group consisting of a polyoxyethylene sorbitan fatty acid ester and digitonin; or

(ii) the far-red dye probe in the formulation has a relative fluorescence, in relative fluorescence units (RFU), and the relative fluoresce of far-red dye probe is decreased by no more than 20% after 30 days of storage.

13 . The diagnostic product of claim 12 , wherein the non-linear surfactant is selected from the group consisting of a polyoxyethylene sorbitan fatty acid ester and digitonin.

14 . The diagnostic product of claim 12 , wherein the non-linear surfactant is a polyoxyethylene sorbitan fatty acid ester selected from the group consisting of polysorbate 20, polysorbate 40, and polysorbate 60.

15 . The diagnostic product of claim 12 , wherein the non-linear surfactant concentration is from about 0.5% (v/v) to about 10% (v/v), from about 1% (v/v) to about 20% (v/v), or from about 1% (v/v) to about 10% (v/v).

16 . The diagnostic product of claim 12 , wherein the far-red dye is a far-red cyanine dye.

17 . The diagnostic product of claim 12 , wherein the far-red cyanine dye is selected from the group consisting of cyanine 5 and cyanine 5.5.

18 . The diagnostic product of claim 12 , wherein the far-red dye probe in the reconstituted stabilized, aqueous far-red dye probe formulation has a relative fluorescence, in relative fluorescence units (RFU), and the relative fluoresce of far-red dye probe is decreased by no more than 20% after 30 days of storage.

19 . The diagnostic product of claim 12 , wherein the stabilized far-red dye probe formulation is a stabilized, reconstituted far-red dye probe formulation.

20 . The diagnostic product of claim 12 , wherein the carrier molecule is a nucleic acid.

Assignments (3)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 072585/0533 Recorded Apr 24, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC.; GEN-PROBE INCORPORATED; BOLDER SURGICAL, LLC; GYNESONICS, INC.
Reel/Frame 075456/0260 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 15, 2025
From: HOLOGIC, INC.; BOLDER SURGICAL, LLC; GYNESONICS, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A.
Reel/Frame 072585/0533 →